by Mariette Le Roux
Scientists Wednesday unveiled a drug combination that destroys antibiotic-resistant germs in mice, potentially opening a new front against chronic and relapsing infections in humans.
Big Pharma had been closely interested in a compound dubbed acyldepsipeptide (ADEP), only to drop it when some germs became resistant to it.
But scientists in the United States reported that, when used alongside conventional antibiotics, ADEP proved to be a relentless killer.
"We decided to pair it to conventional antibiotics.... to stem the propagation of (drug) resistant cells," said study co-author Kim Lewis of Northeastern University in Boston.
The combination "completely sterilised" bacteria in a Petri dish and in mice whose thighs had been severely infected, said Lewis.
"Efficacy in an animal model is actually a pretty good predictor of efficacy in humans, so I think it is entirely realistic" that a drug may result, he added.
Humans rely on antibiotics to fight off a vast array of bacterial diseases, from tonsillitis to tuberculosis.
But antibiotics do not work for all types of bacteria, and in some types where they are effective, germs are evolving worryingly into forms that are resistant to the drug.
Some infections are caused by biofilms—slimy collections of bacterial cells that coat infected areas and block out the immune system, according to a podcast by Nature, accompanying the study in the British journal.
While antibiotics can penetrate those biofilms, they fail to clear up the infection because of so-called "persister cells".
These are hibernating cells within the biofilm that stop dividing or growing and shut down their metabolism.
The dormant cells are the main cause of chronic and relapsing bacterial infections, since conventional antibiotics can target only actively growing bacterial cells.
"We had to look for something that in a persister will activate a function, will corrupt it, force it to kill the cell," said Lewis.
Drug combo triggers cell death
The team tested ADEP in the lab and found it activates a protease in cells—protease is a protein that breaks up other proteins, eventually causing cell death.
In the experiments, the protease degraded proteins in the bacterial cells, causing these molecules to "self-digest", said Lewis.
"It doesn't matter whether that cell was growing, dormant, persister. So that compound has the ability to sterilise an infection," he said.
The reason that pharmaceutical companies had abandoned ADEP as a drug option was because resistance to it developed "pretty readily", according to the study author.
And mutant bacterial cells that do not produce protease are completely resistant to ADEP when the drug is used on its own.
In their experiments, the team used ADEP in conjunction with conventional antibiotics such as rifampicin to wipe out Staphylococcus aureus germs.
"What we found is these mutants that do not have the protease... become susceptible to killing by any antibiotic essentially," said Lewis.
"That is why we get sterilisation when we combine ADEP with virtually any other antibiotic and that of course solves the problem of resistance."
Lewis said his team was working with a biotech company to take these results further.
In a comment also carried by Nature, bacteriologists Kenn Gerdes of Britain's Newcastle University and Hanne Ingmer of the University of Copenhagen rated the chances of a new antibiotic as "probable".
They also noted that Lewis and the team were testing a second class of antibiotic that also activates protease.
"This growing body of results generates hope that antibiotics for the treatment of persistent infections will be available in the future," they said.
Explore further: New substance effectively combats multi-resistant bacteria
More information: Paper: dx.doi.org/10.1038/nature12790
© 2013 AFP
Medical Xpress on facebook
Related Stories
Breakthrough in tracking a cause of chronic infections
Feb 24, 2010
(PhysOrg.com) -- Northeastern University researchers have identified a protein that enables bacterial cells to survive antibiotic treatment.
New substance effectively combats multi-resistant bacteria
Oct 30, 2013
In Europe alone, more than 25,000 people die each year from infections caused by multi-resistant bacteria. Researchers from University of Copenhagen have now developed and characterized a substance that quickly and effectively ...
Addressing the challenge of persister cells in bacterial infections
Sep 15, 2011
Dacheng Ren, assistant professor in the Department of Biomedical and Chemical Engineering in Syracuse University’s L.C. Smith College of Engineering and Computer Science (LCS) and member of the Syracuse ...
Bacterial 'autopsy' could speed antibiotic discovery: study
Sep 20, 2013
(HealthDay)—Scientists say they've found a quicker way to analyze chemicals with bacteria-killing abilities in an advance they hope will speed the development of new antibiotics.
Researchers find compound effective in destroying antibiotic-resistant biofilms
Apr 08, 2010
Researchers at North Carolina State University have found a chemical compound that, when used in conjunction with conventional antibiotics, is effective in destroying biofilms produced by antibiotic-resistant strains of bacteria ...
Recommended for you
Tomato therapy: Engineered veggies target intestinal lipids, improve cholesterol
1 hour ago
UCLA researchers report that tiny amounts of a specific type of lipid in the small intestine may play a greater role than previously thought in generating the high cholesterol levels and inflammation that lead to clogged ...
Compound stymies polyomaviruses in lab tests
2 hours ago
A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine ...
Redesigned protein opens door for safer gene therapy
2 hours ago
A fusion protein engineered by researchers at KU Leuven combining proteins active in HIV and Moloney murine leukaemia virus (MLV) replication may lead to safer, more effective retroviral gene therapy.
UCLA doctors test stem-cell therapy to improve blood flow in angina patients
5 hours ago
Marty Greenfield lives with crushing pain every day due to angina, a condition that is caused by an inadequate supply of blood to the heart. He has suffered a heart attack, and a coronary bypass procedure and angioplasty ...
Researcher finds potential new use for old drugs
10 hours ago
A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found.
Cells show signs of faster aging after depression
Nov 12, 2013
(HealthDay)—The cells of people who have had depression may age more quickly, a new study suggests.
User comments
© Medical Xpress 2011-2013, Phys.org network
by Mariette Le Roux
Scientists Wednesday unveiled a drug combination that destroys antibiotic-resistant germs in mice, potentially opening a new front against chronic and relapsing infections in humans.
Big Pharma had been closely interested in a compound dubbed acyldepsipeptide (ADEP), only to drop it when some germs became resistant to it.
But scientists in the United States reported that, when used alongside conventional antibiotics, ADEP proved to be a relentless killer.
"We decided to pair it to conventional antibiotics.... to stem the propagation of (drug) resistant cells," said study co-author Kim Lewis of Northeastern University in Boston.
The combination "completely sterilised" bacteria in a Petri dish and in mice whose thighs had been severely infected, said Lewis.
"Efficacy in an animal model is actually a pretty good predictor of efficacy in humans, so I think it is entirely realistic" that a drug may result, he added.
Humans rely on antibiotics to fight off a vast array of bacterial diseases, from tonsillitis to tuberculosis.
But antibiotics do not work for all types of bacteria, and in some types where they are effective, germs are evolving worryingly into forms that are resistant to the drug.
Some infections are caused by biofilms—slimy collections of bacterial cells that coat infected areas and block out the immune system, according to a podcast by Nature, accompanying the study in the British journal.
While antibiotics can penetrate those biofilms, they fail to clear up the infection because of so-called "persister cells".
These are hibernating cells within the biofilm that stop dividing or growing and shut down their metabolism.
The dormant cells are the main cause of chronic and relapsing bacterial infections, since conventional antibiotics can target only actively growing bacterial cells.
"We had to look for something that in a persister will activate a function, will corrupt it, force it to kill the cell," said Lewis.
Drug combo triggers cell death
The team tested ADEP in the lab and found it activates a protease in cells—protease is a protein that breaks up other proteins, eventually causing cell death.
In the experiments, the protease degraded proteins in the bacterial cells, causing these molecules to "self-digest", said Lewis.
"It doesn't matter whether that cell was growing, dormant, persister. So that compound has the ability to sterilise an infection," he said.
The reason that pharmaceutical companies had abandoned ADEP as a drug option was because resistance to it developed "pretty readily", according to the study author.
And mutant bacterial cells that do not produce protease are completely resistant to ADEP when the drug is used on its own.
In their experiments, the team used ADEP in conjunction with conventional antibiotics such as rifampicin to wipe out Staphylococcus aureus germs.
"What we found is these mutants that do not have the protease... become susceptible to killing by any antibiotic essentially," said Lewis.
"That is why we get sterilisation when we combine ADEP with virtually any other antibiotic and that of course solves the problem of resistance."
Lewis said his team was working with a biotech company to take these results further.
In a comment also carried by Nature, bacteriologists Kenn Gerdes of Britain's Newcastle University and Hanne Ingmer of the University of Copenhagen rated the chances of a new antibiotic as "probable".
They also noted that Lewis and the team were testing a second class of antibiotic that also activates protease.
"This growing body of results generates hope that antibiotics for the treatment of persistent infections will be available in the future," they said.
Explore further: New substance effectively combats multi-resistant bacteria
More information: Paper: dx.doi.org/10.1038/nature12790
© 2013 AFP
Medical Xpress on facebook
Related Stories
Breakthrough in tracking a cause of chronic infections
Feb 24, 2010
(PhysOrg.com) -- Northeastern University researchers have identified a protein that enables bacterial cells to survive antibiotic treatment.
New substance effectively combats multi-resistant bacteria
Oct 30, 2013
In Europe alone, more than 25,000 people die each year from infections caused by multi-resistant bacteria. Researchers from University of Copenhagen have now developed and characterized a substance that quickly and effectively ...
Addressing the challenge of persister cells in bacterial infections
Sep 15, 2011
Dacheng Ren, assistant professor in the Department of Biomedical and Chemical Engineering in Syracuse University’s L.C. Smith College of Engineering and Computer Science (LCS) and member of the Syracuse ...
Bacterial 'autopsy' could speed antibiotic discovery: study
Sep 20, 2013
(HealthDay)—Scientists say they've found a quicker way to analyze chemicals with bacteria-killing abilities in an advance they hope will speed the development of new antibiotics.
Researchers find compound effective in destroying antibiotic-resistant biofilms
Apr 08, 2010
Researchers at North Carolina State University have found a chemical compound that, when used in conjunction with conventional antibiotics, is effective in destroying biofilms produced by antibiotic-resistant strains of bacteria ...
Recommended for you
Tomato therapy: Engineered veggies target intestinal lipids, improve cholesterol
1 hour ago
UCLA researchers report that tiny amounts of a specific type of lipid in the small intestine may play a greater role than previously thought in generating the high cholesterol levels and inflammation that lead to clogged ...
Compound stymies polyomaviruses in lab tests
2 hours ago
A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine ...
Redesigned protein opens door for safer gene therapy
2 hours ago
A fusion protein engineered by researchers at KU Leuven combining proteins active in HIV and Moloney murine leukaemia virus (MLV) replication may lead to safer, more effective retroviral gene therapy.
UCLA doctors test stem-cell therapy to improve blood flow in angina patients
5 hours ago
Marty Greenfield lives with crushing pain every day due to angina, a condition that is caused by an inadequate supply of blood to the heart. He has suffered a heart attack, and a coronary bypass procedure and angioplasty ...
Researcher finds potential new use for old drugs
10 hours ago
A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found.
Cells show signs of faster aging after depression
Nov 12, 2013
(HealthDay)—The cells of people who have had depression may age more quickly, a new study suggests.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment